The business model of Bayer AG is focused on the development, manufacturing, and sale of healthcare and agricultural products. As a global pharmaceutical and life sciences company, Bayer AG operates in various sectors such as Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. With its innovative research and development, Bayer AG aims to improve people's lives through its products and solutions. By maintaining a diverse portfolio, strong market presence, and strategic partnerships, the company seeks to address global challenges and contribute to a sustainable future in the fields of healthcare and agriculture.

Bayer AG is primarily active in the pharmaceutical, consumer health, and agricultural industries.

The main competitors of Bayer AG in the market include companies like Johnson & Johnson, Novartis AG, and Sanofi. These companies are also prominent players in the healthcare and pharmaceutical sectors. Bayer AG, a leading life sciences company, competes with these global giants in the areas of pharmaceuticals, consumer health, and crop science. With its diversified portfolio and innovative solutions, Bayer AG strives to stay competitive and maintain market leadership in its various segments.

Bayer AG is a renowned German pharmaceutical and life sciences company with a rich history and strong background. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, Bayer initially focused on the production of synthetic dyes. Over time, it diversified its portfolio and entered the fields of healthcare, agriculture, and high-tech materials. Today, Bayer is globally recognized for its contributions to medicine, crop protection, and innovative materials. With a commitment to science and sustainability, Bayer continues to improve lives and address global challenges.

Bayer AG has achieved significant milestones throughout its history. Some notable achievements include the development of Aspirin, a widely recognized pain reliever, and the invention of the first oral contraceptive pill. The company also played a crucial role in introducing genetically modified crops, revolutionizing agriculture practices. Additionally, Bayer AG successfully completed the acquisition of Monsanto Company, a leading agricultural biotechnology company. With a rich history of innovation and successful business ventures, Bayer AG continues to make strides in the fields of healthcare, pharmaceuticals, and agriculture, solidifying its position as a global industry leader.

Bayer AG is primarily present in numerous countries and regions worldwide. As a global pharmaceutical and life sciences company, Bayer AG has established a strong presence across Europe, North America, Asia Pacific, and Latin America. Specifically, in Europe, the company has a significant presence in Germany, where its headquarters are located. Furthermore, Bayer AG has a substantial footprint in the United States, contributing to its strong presence in North America. The company's operations extend into key markets in China and other Asian countries as well. With its global reach, Bayer AG aims to serve patients and customers around the world with innovative solutions and products.

Bayer AG represents values of innovation, sustainability, and responsibility. As a global company, Bayer focuses on providing solutions that improve people's lives and contribute to societal progress. Their corporate philosophy emphasizes ethical behavior, fairness, and integrity in all business activities. Bayer is committed to scientific excellence and advances in areas such as healthcare, agriculture, and nutrition. They strive to create a more sustainable future by developing environmentally friendly products and reducing their ecological footprint. With a strong emphasis on research and development, Bayer AG aims to continuously drive growth and make a positive impact worldwide.

Analysts currently set an average price target of 42,36 EUR for the Bayer stock (median: 41,92 EUR), implying −9,6 % versus the latest price. The consensus is based on 29 analyst ratings.

Bayer Ciljne cijene analitičara 2026

29 analysts currently rate the Bayer stock: 17 recommend buying, 10 holding and 2 selling. For 2026, analysts expect Bayer to generate revenue of 45,68 milijardi EUR and earnings per share of 4,38 EUR.

Bayer Ciljne cijene analitičara 2026

The Bayer share (BAYN.DE) is listed on 14 stock exchanges, including: NASDAQ (BAYZF), XETRA (BAYN.DE), Frankfurt (BAYN.F), München (BAYN.MU), Stuttgart (BAYN.SG), Düsseldorf (BAYN.DU), Berlin (BAYN.BE), Hamburg (BAYN.HM).

The Bayer AG is a German company that operates in various business sectors. The company is active in the chemical and pharmaceutical industry and offers a wide range of products and services. Pharma and Health One of Bayer's most well-known business sectors is pharma and health. The company produces a variety of medications used for treating diseases such as diabetes, cancer, cardiovascular diseases, and many more. The most well-known medications include the pain reliever Aspirin, the contraceptive Yaz, and the cancer medication Nexavar. Crop Science Another important business sector of Bayer is Crop Science. Bayer produces seeds and plant protection products for the agribusiness sector. The company offers a wide range of products for the cultivation of crops such as grains, vegetables, and fruits. The company also supports farmers in the efficient use of water and energy for sustainable agriculture. Bayer Crop Science is a key player in the global agricultural landscape. Consumer Health Bayer also has a Consumer Health business sector that offers a variety of products for health and personal care. The company produces medications for minor illnesses and diseases such as cold and flu, as well as self-care products such as pain ointments, antiseptics, skin creams, and vitamins. The most well-known products include Coppertone sunscreen and the pain reliever Aleve. Animal Health Bayer also utilizes its expertise in animal health by producing medications and services. This business sector focuses on the health and well-being of livestock and pets. The company has an extensive range of products for the treatment and prevention of disease-related risks in pets as well as livestock. Bayer also has various business sectors focusing on the production of chemicals, materials, and technologies for the production of plastics, paints, adhesives, high-tech products, and more. Overall, Bayer AG's business model is oriented towards strong diversification to minimize risks and seize opportunities in various markets. With a wide range of products and a strong presence in different regions, Bayer continuously generates a high volume of revenue through its strong research and development and is an important company for the German economy.

Prihod od očekivane od Bayer iznosi 45,68 milijardi EUR. Ova brojka temelji se na trenutnim financijskim podacima i odražava poslovnu uspješnost poduzeća.

Dobit od očekivane od Bayer iznosi 4,30 milijardi EUR. Neto dobit pokazuje profitabilnost poduzeća nakon odbitka svih troškova.

Omjer cijene i zarade (KGV) od Bayer trenutno je 10,93. KGV uspoređuje trenutnu cijenu dionice sa zaradom po dionici i pomaže ulagačima da procijene vrednovanje dionice Bayer.

Omjer cijene i prihoda (KUV) od Bayer trenutno je 1,03. KUV uspoređuje tržišnu kapitalizaciju s godišnjim prihodom i služi kao pokazatelj vrednovanja dionice Bayer.

Eulpool Quality Score za Bayer je 1/10.

ISIN od Bayer je DE000BAY0017. ISIN (International Securities Identification Number) je globalno jedinstvena identifikacija za vrijednosne papire.

WKN od Bayer je BAY001. WKN (Wertpapierkennnummer) je šestoznačni njemački broj za identifikaciju vrijednosnih papira.

Ticker od Bayer je BAYN.DE. Simbol tickera koristi se za trgovanje dionicama Bayer na burzi.

Tijekom proteklih 12 mjeseci, Bayer je isplatio dividendu od 0,11 EUR . To odgovara prinosu dividende od oko 0,23 %. Za nadolazeće 12 mjeseci, Bayer se očekuje da isplati dividendu od 0,11 EUR.

Sadašnja dividendna randita Bayer iznosi 0,23 %.

Bayer isplaćuje dividendu, distribuiranu u mjesecima , , , .

Bayer je isplaćivao dividende svake godine u proteklih 36 godina.

Za nadolazeće 12 mjeseci očekuju se dividende u vrijednosti od 0,11 EUR. To odgovara prinosu dividende od 0,24 %.

Bayer je dodijeljen sektoru 'Zdravstvo'.

Kako bi primio zadnju dividendu od Bayer od u vrijednosti od 0,11 EUR, trebao si imati dionicu u svojem portfelju prije ex-datuma .

Isplata zadnje dividende izvršena je .

U godini 2025, Bayer je isplatio 0,11 EUR kao dividende.

Dividende od Bayer distribuiraju se u EUR.